Iris Acquisition CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q/A: Iris Acquisition Corp Restates Financials Due to Related Party Transaction and Material Weakness
Iris Acquisition Corp restated its financials for the period ended September 30, 2024, due to an undisclosed related party transaction and the identification of a material weakness in internal control over financial reporting.
10-Q/A: Iris Acquisition Corp Restates Financials Due to Related Party Transaction and Material Weakness
Iris Acquisition Corp files an amended 10-Q/A to restate its financials for the period ended June 30, 2024, due to an undisclosed related party transaction and the identification of a material weakness in internal control over financial reporting.
10-Q: Iris Acquisition Corp Reports Q3 2024 Results Amidst Business Combination Extension and Delisting
Iris Acquisition Corp's Q3 2024 report reveals a net loss, ongoing business combination efforts, and a delisting from Nasdaq, with trading now on the OTC Pink Marketplace.
Iris Acquisition Corp reported a net loss for the second quarter of 2024 and is facing challenges in completing its business combination with Liminatus Pharma.
Iris Acquisition Corp reported a net loss of $858,231 for the quarter ended March 31, 2024, as it continues to pursue a business combination with Liminatus Pharma.
Iris Acquisition Corp reported a net loss of $323,891 for the third quarter of 2023, as it continues to pursue a business combination with Liminatus Pharma.